| 2 -0.27 (-11.89%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.92 |
1-year : | 3.37 |
| Resists | First : | 2.5 |
Second : | 2.89 |
| Pivot price | 2.27 |
|||
| Supports | First : | 1.87 |
Second : | 1.55 |
| MAs | MA(5) : | 2.26 |
MA(20) : | 2.37 |
| MA(100) : | 2.67  |
MA(250) : | 1.85 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 29.4 |
D(3) : | 31.5 |
| RSI | RSI(14): 34.6 |
|||
| 52-week | High : | 4.3 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAUT ] has closed below the lower bollinger band by 13.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NAUT ] is to continue within current trading range. It is unclear right now based on current values. 65.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.25 - 2.26 | 2.26 - 2.27 |
| Low: | 1.84 - 1.86 | 1.86 - 1.87 |
| Close: | 2.04 - 2.07 | 2.07 - 2.08 |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Thu, 25 Jun 2026
NAUT Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 24 Jun 2026
Press Release: Nautilus Biotechnology Reports First Quarter 2026 Financial Results - Moomoo
Mon, 22 Jun 2026
[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity - Stock Titan
Mon, 22 Jun 2026
[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity - Stock Titan
Mon, 22 Jun 2026
[Form 4] Nautilus Biotechnology, Inc. Insider Trading Activity - Stock Titan
Mon, 22 Jun 2026
Nautilus Biotechnology Inc (NAUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 127 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 33.2 (%) |
| Held by Institutions | 43.5 (%) |
| Shares Short | 760 (K) |
| Shares Short P.Month | 716 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -33.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -50 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -4.49 |
| PEG Ratio | 0 |
| Price to Book value | 1.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|